DK2300452T3 - 5 -[5- [2-(3,5 -(bis(trifluoromethyl)phenyl) -2 - methylpropanoylmethylamino ]-4 -(4-fluoro -2-methylphenyl)]-2-pyridinyl -2-alkyl -prolinamid som NK1 receptor antagonister - Google Patents
5 -[5- [2-(3,5 -(bis(trifluoromethyl)phenyl) -2 - methylpropanoylmethylamino ]-4 -(4-fluoro -2-methylphenyl)]-2-pyridinyl -2-alkyl -prolinamid som NK1 receptor antagonisterInfo
- Publication number
- DK2300452T3 DK2300452T3 DK09745725.3T DK09745725T DK2300452T3 DK 2300452 T3 DK2300452 T3 DK 2300452T3 DK 09745725 T DK09745725 T DK 09745725T DK 2300452 T3 DK2300452 T3 DK 2300452T3
- Authority
- DK
- Denmark
- Prior art keywords
- methylpropanoylmethylamino
- prolinamide
- pyridinyl
- methylphenyl
- trifluoromethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0808747.0A GB0808747D0 (en) | 2008-05-14 | 2008-05-14 | Novel compounds |
| PCT/EP2009/055700 WO2009138393A1 (en) | 2008-05-14 | 2009-05-12 | 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as nk1 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2300452T3 true DK2300452T3 (da) | 2014-02-17 |
Family
ID=39571329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09745725.3T DK2300452T3 (da) | 2008-05-14 | 2009-05-12 | 5 -[5- [2-(3,5 -(bis(trifluoromethyl)phenyl) -2 - methylpropanoylmethylamino ]-4 -(4-fluoro -2-methylphenyl)]-2-pyridinyl -2-alkyl -prolinamid som NK1 receptor antagonister |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US8344005B2 (da) |
| EP (1) | EP2300452B1 (da) |
| JP (1) | JP5465716B2 (da) |
| KR (1) | KR101567116B1 (da) |
| CN (1) | CN102105458B (da) |
| AR (1) | AR071721A1 (da) |
| AU (1) | AU2009248102B8 (da) |
| BR (1) | BRPI0911990B1 (da) |
| CA (1) | CA2724219C (da) |
| CL (1) | CL2009001146A1 (da) |
| DK (1) | DK2300452T3 (da) |
| EA (1) | EA019037B1 (da) |
| ES (1) | ES2446866T3 (da) |
| GB (1) | GB0808747D0 (da) |
| IL (1) | IL209197A (da) |
| MX (1) | MX2010012421A (da) |
| PE (1) | PE20091847A1 (da) |
| PL (1) | PL2300452T3 (da) |
| TW (1) | TWI444376B (da) |
| UY (1) | UY31824A (da) |
| WO (1) | WO2009138393A1 (da) |
| ZA (1) | ZA201007904B (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8426450B1 (en) * | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| PL3067349T3 (pl) | 2013-11-08 | 2018-06-29 | Kissei Pharmaceutical Co., Ltd. | Pochodna karboksymetylopiperydyny |
| TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
| WO2016021562A1 (ja) * | 2014-08-06 | 2016-02-11 | キッセイ薬品工業株式会社 | シアノチオフェン誘導体 |
| WO2018197638A1 (en) | 2017-04-27 | 2018-11-01 | Nerre Therapeutics Limited | Novel use of (5r)-5-[5-[{2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl}(methyl)amino]-4-(4-fluoro-2-methylphenyl)-2-pyridinyl]-2-methyl-d-prolinamide |
| US20230105795A1 (en) * | 2020-01-30 | 2023-04-06 | Mohammad JAVED | Combination drug therapies for cns disorders |
| JP2023531863A (ja) * | 2020-06-02 | 2023-07-26 | ネッレ セラピューティクス リミテッド | 肺の機械的損傷によって促進される肺線維症状態の治療で使用するためのニューロキニン（ｎｋ）－１受容体拮抗薬 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1035115B1 (en) | 1999-02-24 | 2004-09-29 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
| CA2364665C (en) | 1999-02-24 | 2009-09-15 | F. Hoffmann-La Roche Ag | Phenyl- and pyridinyl derivatives |
| US6303790B1 (en) | 1999-11-29 | 2001-10-16 | Hoffman-La Roche Inc. | Process for the preparation of pyridine derivatives |
| SI1303490T1 (sl) | 2000-07-14 | 2008-10-31 | Hoffmann La Roche | N-oksidi kot predzdravila NK 1 receptorskega antagonista 4-fenil-piridin derivatov |
| TWI287003B (en) | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
| TWI259180B (en) | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
| BR0209151A (pt) | 2001-04-23 | 2004-07-13 | Hoffmann La Roche | Uso de antagonistas de receptor nk-1 contra hiperplasia prostática benigna |
| US20030083345A1 (en) | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
| US6849624B2 (en) | 2001-07-31 | 2005-02-01 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted amides |
| ES2291891T3 (es) * | 2003-07-03 | 2008-03-01 | F. Hoffmann-La Roche Ag | Antagonistas duales de nk1/nk3 para tratamiento de esquizofrenia. |
| CN1984891B (zh) | 2004-07-06 | 2012-08-08 | 弗·哈夫曼-拉罗切有限公司 | 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法 |
| US20060030600A1 (en) | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
| AR058805A1 (es) * | 2005-09-09 | 2008-02-27 | Smithkline Beecham Corp | Derivados biciclicos de piridina utiles como agentes antipsicoticos |
| US7855218B2 (en) * | 2005-10-10 | 2010-12-21 | Convergence Pharmaceuticals Limited | Compounds |
-
2008
- 2008-05-14 GB GBGB0808747.0A patent/GB0808747D0/en not_active Ceased
-
2009
- 2009-05-12 CL CL2009001146A patent/CL2009001146A1/es unknown
- 2009-05-12 EA EA201071299A patent/EA019037B1/ru not_active IP Right Cessation
- 2009-05-12 US US12/991,515 patent/US8344005B2/en active Active
- 2009-05-12 EP EP09745725.3A patent/EP2300452B1/en active Active
- 2009-05-12 CN CN2009801275140A patent/CN102105458B/zh active Active
- 2009-05-12 TW TW098115612A patent/TWI444376B/zh not_active IP Right Cessation
- 2009-05-12 KR KR1020107027927A patent/KR101567116B1/ko active IP Right Grant
- 2009-05-12 UY UY0001031824A patent/UY31824A/es not_active Application Discontinuation
- 2009-05-12 PL PL09745725T patent/PL2300452T3/pl unknown
- 2009-05-12 PE PE2009000650A patent/PE20091847A1/es not_active Application Discontinuation
- 2009-05-12 MX MX2010012421A patent/MX2010012421A/es active IP Right Grant
- 2009-05-12 CA CA2724219A patent/CA2724219C/en active Active
- 2009-05-12 AR ARP090101713A patent/AR071721A1/es not_active Application Discontinuation
- 2009-05-12 BR BRPI0911990-6A patent/BRPI0911990B1/pt active IP Right Grant
- 2009-05-12 AU AU2009248102A patent/AU2009248102B8/en not_active Ceased
- 2009-05-12 JP JP2011508893A patent/JP5465716B2/ja active Active
- 2009-05-12 DK DK09745725.3T patent/DK2300452T3/da active
- 2009-05-12 WO PCT/EP2009/055700 patent/WO2009138393A1/en active Application Filing
- 2009-05-12 US US12/464,171 patent/US20090286836A1/en not_active Abandoned
- 2009-05-12 ES ES09745725.3T patent/ES2446866T3/es active Active
-
2010
- 2010-11-04 ZA ZA2010/07904A patent/ZA201007904B/en unknown
- 2010-11-08 IL IL209197A patent/IL209197A/en active IP Right Grant
-
2012
- 2012-11-20 US US13/681,925 patent/US8822504B2/en active Active
-
2014
- 2014-05-16 US US14/280,280 patent/US9006271B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0914772A2 (pt) | compostos heterocíclicos 1,2-dissubstituídos | |
| DK2300452T3 (da) | 5 -[5- [2-(3,5 -(bis(trifluoromethyl)phenyl) -2 - methylpropanoylmethylamino ]-4 -(4-fluoro -2-methylphenyl)]-2-pyridinyl -2-alkyl -prolinamid som NK1 receptor antagonister | |
| BRPI0923786A2 (pt) | compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos | |
| DK2069374T4 (da) | Krystallinske solvater af (1s)-1,5-anhydro-1-c-(3-((phenyl) methyl)phenyl)-d-glucitolderivater med alkoholer som sglt2-inhibitorer til behandling af diabetes | |
| BRPI0817537A2 (pt) | 4-[3-(4-ciclopropanocarbonil-piperazina-i-carboni-,-fl uoro-benzil]-2h-ftalazin-1-ona | |
| DK2089382T3 (da) | Substituerede diazepan-forbindelser som orexin-receptor-antagonister | |
| RU2465270C3 (ru) | Полиморфная форма 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-она | |
| DK2010498T3 (da) | Syntese af acylaminoalkenylenamider, der kan anvendes som substans P-antagonister | |
| DK2206710T3 (da) | Indolderivater som s1p1-receptor agonister | |
| DK2200985T3 (da) | 1,3-Disubstituerede 4-(aryl--X-phenyl)-1H-pyridin-2-oner | |
| ATE509928T1 (de) | 8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten | |
| BRPI0815440A2 (pt) | 5-substituidos 2- (alcoximetil) furanos | |
| BRPI0811578A2 (pt) | Tetramatos substituídos por 3-(2-alcóxi-fenila) | |
| DK2102205T3 (da) | Pyridopyrazinderivater anvendelige som herbicidale forbindelser | |
| ATE490254T1 (de) | Imidazoä1,2-aüpyridin-verbindungen als vegf-r2- hemmer | |
| BRPI0922904A2 (pt) | "compostos" | |
| DK2089367T3 (da) | Pyrazolinforbindelser som mineralocorticoidreceptor-antagonister | |
| DE602006020447D1 (de) | Niacin-rezeptoragonisten, zusammensetzungen mit de | |
| RS52594B (en) | NON-STEROID ANTAGONISTS OF MINERALOCORTICOID RECEPTORS OBTAINED FROM 6H-DIBENZO [B, E] OXPINE | |
| DK2125714T3 (da) | Hydrochloridsalt af 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamid | |
| BRPI0811446A2 (pt) | " 2-[4-(pirazol-4-ilalquil)piperazin-1-il]-3-fenil pirazinas e piridinas e 3-[4-(pirazol-4-ilalquil)piperazin-1-il]-2-fenil piridinas como antagonistas de receptor 5-ht7" | |
| BRPI0916363A2 (pt) | derivados de 4,5-di-hidro-oxazol-2-ila | |
| SMT201200063B (it) | Composti 4-[2-(-fluorofenossimetil)fenil]piperidinici | |
| DK1899324T3 (da) | Benzimidazolcarboxamid-forbindelser som 5-HT4-receptoragonister | |
| BRPI1014669A2 (pt) | antagonistas ccr3 de arilsulfonamida 2,5-dissubstituída |